Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2015
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Everolimus (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 30 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 03 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Jul 2014 Planned End Date changed from 1 Aug 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov record.